CEVOLUTION
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 380 patients (estimated)
- Sponsors
- Hoffmann-La Roche
- Tags
- Bispecific Antibody, T Cell Engager (TCE), FCRH5, Randomization
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2260
- NCT Identifier
- NCT07555938
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.